(Q40088973)

17 September 2017

1 reference

title

Recent progress in the medicinal chemistry of 2,4-diaminopyrimidines (English)

1 reference

17 September 2017

Roth B

1

1 reference

PubMed ID

6129679

17 September 2017

Cheng CC

series ordinal

2

1 reference

17 September 2017

1 January 1982

1 reference

Progress in medicinal chemistry

17 September 2017

1 reference

17 September 2017

19

1 reference

17 September 2017

269-331

1 reference

The Structure and Synthesis of the Liver L. casei Factor

17 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Pyrimido [4,5-b] pyrazines; 2,4-diaminopyrimido [4,5-b] pyrazine and derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Antagonist for pteroylglutamic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Observations on the Effect of 4-Amino-Pteroylglutamic Acid on Mice

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

5-BENZYL-2,4-DIAMINOPYRIMIDINES AS ANTIBACTERIAL AGENTS. I. SYNTHESIS AND ANTIBACTERIAL ACTIVITY IN VITRO.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

A metabolite of paludrine with high antimalarial activity

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

On the enzymic reduction of folic acid by a purified hydrogenase

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Inhibition of dihydrofolic reductase by aminopterin and amethopterin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

DIFFERENTIAL INHIBITION OF DIHYDROFOLIC REDUCTASE FROM DIFFERENT SPECIES

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Dihydrofolate reductases as targets for inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Dihydrofolate Reductase: X-ray Structure of the Binary Complex with Methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

The binding of trimethoprim to bacterial dihydrofolate reductase

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Pharmacokinetics.Selectivity of action related to physicochemical properties and kinetic patterns of anticancer drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Recent advances in column chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Purification of dihydrofolic reductase from chicken liver by affinity chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Nucleotide sequence of the E. coli gene coding for dihydrofolate reductase

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

The Amino-Acid Sequence of the Dihydrofolate Reductase of a Trimethoprim-Resistant Strain of Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Dihydrofolate reductase: the amino acid sequence of the enzyme from a methotrexate-resistant mutant of Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Dihydrofolate reductase from lactobacillus casei: N-terminal sequence and comparison with the substrate binding region of other reductases

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Amino acid sequence of dihydrofolate reductase from an amethopterin-resistant strain ofLactobacillus casei

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Amino-acid sequence of dihydrofolate reductase from a methotrexate-resistant mutant of Streptococcus faecium and identification of methionine residues at the inhibitor binding site

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Micro-Edman degradation: the use of high pressure liquid chromatography and gas chromatography in the amino terminal sequence determination of 8 nanomoles of dihydrofolate reductase from a mouse sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Dihydrofolate Reductase from Bovine Liver. Enzymatic and Structural Properties

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Primary structure of chicken liver dihydrofolate reductase

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Comparative Studies on Dihydrofolate Reductases fromPlasmodium falciparumandAotus trivirgatus*

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Action of pyrimethamine and related drugs againstPlasmodium knowlesi in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Dihydrofolate Reductase inPlasmodium lophuraeand Duckling Erythrocytes*

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Dihydrofolate reductase: thymidylate synthase, a bifunctional polypeptide from Crithidia fasciculata

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Dihydrofolate reductase from the L1210R murine lymphoma. Fluorometric measurements of the interaction of the enzyme with coenzymes, substrates, and inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Kinetics of ternary complex formation between dihydrofolate reductase, coenzyme, and inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Carbon-13 nuclear magnetic resonance study of protonation of methotrexate and aminopterin bound to dihydrofolate reductase

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Dihydrofolate reductase from a resistant subline of the L1210 lymphoma. Purification by affinity chromatography and ultraviolet difference spectrophotometric and circular dichroic studies

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Ultraviolet difference-spectroscopic studies of substrate and inhibitor binding to Lactobacillus casei dihydrofolate reductase

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Methotrexate and folate binding to dihydrofolate reductase. Separate characterization of the pteridine and p-aminobenzoyl binding sites by resonance Raman spectroscopy

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

The use of saturation transfer NMR experiments to monitor the conformational selection accompanying ligand-protein interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Nuclear magnetic resonance studies of the binding of trimethoprim to dihydrofolate reductase

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

1 H nuclear magnetic resonance studies of Lactobacillus casei dihydrofolate reductase: effects of substrate and inhibitor binding on the histidine residues

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Histidine residues of Lactobacillus casei dihydrofolate reductase: paramagnetic relaxation and deuterium-exchange studies and partial assignments

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Proton nuclear magnetic resonance studies of the effects of ligand binding on tryptophan residues of selectively deuterated dihydrofolate reductase from Lactobacillus casei

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Interpretation of nuclear magnetic resonance spectra for Lactobacillus casei dihydrofolate reductase on the basis of the x-ray structure of the enzyme-methotrexate-NADPH complex

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Trimethoprim, a sulphonamide potentiator

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

The inhibition of dihydrofolate reductase by folate analogues: structural requirements for slow- and tight-binding inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Quantitative structure-selectivity relationships. Comparison of the inhibition of Escherichia coli and bovine liver dihydrofolate reductase by 5-(substituted-benzyl)-2,4-diaminopyrimidines

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Dihydrofolate reductase hysteresis and its effect of inhibitor binding analyses

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

2,4-Diamino-5-benzylpyrimidines and analogues as antibacterial agents. 5. 3',5'-Dimethoxy-4'-substituted-benzyl analogues of trimethoprim

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Quantitative structure-activity relationship of 5-(X-benzyl)-2,4-diaminopyrimidines inhibiting bovine liver dihydrofolate reductase

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Cooperativity in ligand binding to dihydrofolate reductase

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

2,4-Diamino-5-benzylpyrimidines and analogues as antibacterial agents. 2. C-Alkylation of pyrimidines with Mannich bases and application to the synthesis of trimethoprim and analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Bacterial growth kinetics of E. coli in the presence of various trimethoprim derivatives alone and in combination with sulfonamides.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

2,4-Diamino-5-benzylpyrimidines as antibacterial agents. 4. 6-Substituted trimethoprim derivatives from phenolic Mannich intermediates. Application to the synthesis of trimethoprim and 3,5-dialkylbenzyl analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

2,4-Diamino-5-benzylpyrimidines and analogues as antibacterial agents. 3. C-Benzylation of aminopyridines with phenolic Mannich bases. Synthesis of 1- and 3-deaza analogues of trimethoprim

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Synthesis and chemotherapeutic activity of two metabolites of trimethoprim.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Inhibition of dihydrofolate reductase: structure-activity correlations of 2,4-diamino-5-benzylpyrimidines based upon molecular shape analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Synthesis of trimethoprim variations. Replacement of CH 2 by polar groupings

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

The use of triazine inhibitors in mapping the active site region of Lactobacillus casei dihydrofolate reductase

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Dihydrofolate reductase inhibition by 2,4-diaminotriazines: A structure-activity study

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Studies on condensed pyrimidine systems. XXV. 2,4-diaminopyrido[2,3-d]pyrimidines. Biological data

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Observations on two Plasmodium falciparum infections with an abnormal response to chloroquine

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Malaria prevention in travellers from the United Kingdom. Report of meetings convened by the Ross Institute

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

The Evaluation of Sulfonamides, Alone or in Combination with Pyrimethamine, in the Treatment of Multi-Resistant Falciparum Malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Combined therapy for chloroquine-resistant, Plasmodium falciparum infection. Concurrent use of long-acting sulphormethoxine and pyrimethamine

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Experimental studies of the potentiation of proguanil and pyrimethamine by dapsone usingPlasmodium bergheiin white mice

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Effect of 2,4-diamino-5-(p-chlorophenoxy)-6-methylpyrimidine and 2,4-diamino-6,7-diphenylpteridine on chloroguanide-resistant strain of Plasmodium gallinaceum.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Resistance of pyrimethamine-resistant strain of Plasmodium gallinaceum to certain 2,4-diamino-pyrimidines and related compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Treatment of Acute Falciparum Malaria With Sulfalene and Trimethoprim

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Treatment of falciparum malaria with sulfalene and trimethoprim.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Treatment of acute falciparum malaria from Vietnam with trimethoprim and sulfalene.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

1 reference

7 January 2021

Development of New Antimalarial Drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Antimalarial activity of some novel derivatives of 2,4-diamino-5(p-chlorophenyl)-6-ethylpyrimidine (pyrimethamine)

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Synthesis of 2,4-diamino-5-[4-arylthiophenyl]-and 5-[4-arylsulfonylphenyl]pyrimidines as antimalarials

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Antimalarial activities of some 3,5-diamino-as-triazine derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Studies on the chemotherapy of malaria. (III). Treatment of falciparum malaria in the Gambia, with BRL 50216 (4,6-diamino-(3, 4-dichlorobenzyloxy)-1,2-dihydro-2 2-dimethyl-1,3,5-triazine hydrochloride) alone and in combination with sulphonamides,.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Drug potentiation against pre-erythrocytic stages of Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Antimalarial drugs. 24. Folate antagonists. 2. 2,4-Diamino-6-{[aralkyl and (heterocyclic)methyl]amino}quinazolines, a novel class of antimetabolites of interest in drug-resistant malaria and Chagas' disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Folate antagonists. 9. 2,4-Diamino-6-[(aralkyl)alkylamino]quniazolines, a potent class of antimetabolites with prodigious antimalarial effects

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

PAM 1392 [2,4-diamino-6-(3,4-dichlorobenzylamino) Quinazoline] as a chemotherapeutic agent: Plasmodium berghei, P. cynomolgi, P. knowlesi, and Trypanosoma cruzi

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Antimalarial activity of 2,4-diamino-6-[(3,4-dichlorobenzyl) nitros-amino] quinazoline (CI-679 base) and CI-679 acetate. Laboratory studies in mice and rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Folate antagonists. 18. Synthesis and antimalarial effects of N6-(arylmethyl)-N6-methyl-2,4,6-pteridinetriamines and related N6,N6-disubstituted 2,4,6-pteridinetriamines

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Antimalarial drugs. 40. Folate antagonists. 12. Antimalarial and antibacterial effects of 2,4-diamino-6-[(aralkyl and alicyclic)thio-, sulfinyl-, and sulfonyl]quinazolines

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Uptake as a Determinant of Methotrexate Response in Mouse Leukemias

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

The characteristics of the membrane transport of amethopterin and the naturally occurring folates

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Detective transport of amethopterin (methotrexate) as a mechanism of resistance to the antimetabolite in L5178Y leukemic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

On the role of drug penetration in amethopterin resistance of Sarcoma-180 cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Changes of molecular properties associated with the development of resistance against methotrexate in human lymphoblastoid cells

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Studies of the action of 4-aminopteroylglutamic acid and its congeners in mammals

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

The relative toxicites of methotrexate and aminopterin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Analogs of methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Antibiotics alter methotrexate metabolism and excretion

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Reinvestigation of methotrexate metabolism in rodents

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

The identity of rabbit-liver methotrexate oxidase

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Metabolism of folate antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

The enzymic oxidation of certain folic acid antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

The Metabolite of 3',5'-Dichloro-4-amino-4-deoxy-N10-methylpteroylglutamic Acid (Dichloromethotrexate)

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

THE PHYSIOLOGIC DISPOSITION OF DICHLOROMETHOTREXATE-C136 IN MAN

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Eradication Of Leukaemic Cells (L1210) by Methotrexate and Methotrexate Plus Citrovorum Factor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Toxic and therapeutic effects of methotrexate-folinic acid (Leucovorin) in advanced cancer and leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

The role of chemotherapy in the management of cancer of the head and neck: A review

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

High dose methotrexate with citrovorum factor in adult resistant lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Development of a combination chemotherapy program for adult acute leukemia: CAM and CAM-L

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Weekly high-dose methotrexate-citrovorum factor in osteogenic sarcoma.Pre-surgical treatment of primary tumor and of overt pulmonary metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

L-asparaginase induced alteration of amethopterin (methotrexate) activity in mouse leukemia L5178Y

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

The reversal of methotrexate toxicity by thymidine with maintenance of antitumour effects

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Enzymatic cleavage of methotrexate provides a method for prevention of drug toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Role of thymidylate synthetase activity in development of methotrexate cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Methotrexate analogs. 11. Unambiguous chemical synthesis and in vitro biological evaluation of .alpha.- and .gamma.-monoesters as potential prodrugs

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Methotrexate analogs. 2. A facile method of preparation of lipophilic derivatives of methotrexate and 3',5'-dichloromethotrexate by direct esterification

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Effects of methotrexate esters and other lipophilic antifolates on methotrexate-resistant human leukemic lymphoblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Antineoplastic activity of lipid-soluble dialkyl esters of methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Effect of lipid-soluble esters of methotrexate on DNA synthesis in human skin.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Methotrexate analogs. 3. Synthesis and biological properties of some side-chain altered analogs.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Inhibition of nucleic acid synthesis by the di-n-butyl ester of methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Methotrexate di-n-butyl ester effects on thymidine metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Potential anticancer agents. 17. Analogues of methotrexate with a tripeptide side chain

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Methotrexate analogs. 10. Direct coupling of methotrexate and diethyl L-glutamate in the presence of peptide bond-forming reagents

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Methotrexate analogs. 8. Synthesis and biological evaluation of bisamide derivatives as potential prodrugs

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Methotrexate analogues. 13. Chemical and pharmacological studies on amide, hydrazide, and hydroxamic acid derivatives of the glutamate side chain

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

On the nature of permeability of sarcoma-180 cells to amethopterin in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

The effect of organic acids on renal clearance of methotrexate in man

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Liver Damage due to Methotrexate in Patients with Psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Hepatotoxicity in Wistar rats following chronic methotrexate administration: a model of human reaction

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Methotrexate analogs. 6. Replacement of glutamic acid by various amino acid esters and amines

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Increased dihydrofolate reductase activity as a possible basis of drug resistance in leukaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

CLINICAL STUDIES OF DICHLOROMETHOTREXATE (NSC 29630)

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Methotrexate analogs. 12. Synthesis and biological properties of some aza homologs

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Synthesis and antifolate activity of isoaminopterin.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Antifolate Activity of Isoaminopterin in HeLa Cells

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Synthesis and antifolate activity of 10-deazaminopterin.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Folate analogues altered in the C9-N10 bridge region. 10-Oxafolic acid and 10-oxaaminopterin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Synthesis and biologic evaluation of 7-hydroxymethotrexate, 7-methylaminopterin, and 7-methylmethotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Folic acid analogs. I. p-[[(2,4-Diamino-5-pyrimidinyl)methyl]amino]benzoyl-L-glutamic acid and related compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Folic acid analogs. II. p-[(2,6-Diamino-8-purinyl)methyl]amino-benzoyl-L-glutamic acid and related compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Deaza aalogues of amethopterin (methotrexate)

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Potential folic acid antagonists. VI. Syntheses of 1- and d 3-deazamethotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Pyrimido[5,4-e]-as-triazines. VIII. Synthesis of 7-azaaminopterin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Quinazolines as inhibitors of dihydrofolate reductase. 4. Classical analogues of folic and isofolic acids

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Quinazolines. VI. Synthesis of 2,4-diaminoquinazolines from anthranilonitriles

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Quinazolines as inhibitors of dihydrofolate reductase. 1

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Quinazolines as inhibitors of dihydrofolate reductase. 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Quinazoline antifolates as inhibitors of dihydrofolate reductase from human leukemia cells

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Studies with a 2,4-diamino-5-chloro-quinazoline antifolate: in vitro and invivo correlates in normal and lymphosarcoma dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Multivariate analysis and quantitative structure-activity relationships. Inhibition of dihydrofolate reductase and thymidylate synthetase by quinazolines

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Potential anticancer agents. 10. Synthesis of N-(4((2,4-diamino-7-pteridyl)methyl)-N10-methylamino)benzoyl)glutamic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Synthesis and biological activity of some 5-(1-adamantyl)pyrimidines. 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Synthesis and biological activity of some 5-(1-adamantyl)pyrimidines. 2

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Synthesis and biological activity of some 5-substituted 2,4-diamino-6-alkylpyrimidines. 3

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Comparison of the Antitumor Activity and Toxicity of 2,4-Diamino-5-(1-adamantyl)-6- methylpyrimidine and 2,4-Diamino-5-(1-adamantyl)-6-ethylpyrimidine 2

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Hydrophobic interactions between the 5-alkyl group of 2,4-diamino-6-methylpyrimidines and dihydrofolate reductase

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Synthesis and antifolate activity of new diaminopyrimidines and diaminopurines in enzymatic and cellular systems

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Mapping of dihydrofolate-reductase receptor site by correlation with minimal topological (steric) differences

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Methodichlorophen as anti-tumor drug

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Initial clinical experience with a simultaneous combination of 2,4-diamino-5(3?,4?-dichlorophenyl)-6-methylpyrimidine (DDMP) with folinic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Inhibition of histamine methylation by antimalarial drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

ANTHELMINTIC AGENTS. 1,2-DIHYDRO-S-TRIAZINES

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Analogs of tetrahydrofolic acid. XXVII. Hydrophobic bonding to dihydrofolic reductase by 2-amino-4,6-disubstituted-5-alkylpyrimidines and 1-alkyl-4,6-diamino-1,2-dihydro-s-triazines

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Differential Binding to the Hydrophobic Bonding Region of T2 Phage Induced, Escherichia coli B, and Pigeon Liver Dihydrofolic Reductases

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Irreversible Enzyme Inhibitors. CVIII.1,2 6-(p-Chloroacetylanilinomethyl)-5-(p-chlorophenyl)-2, 4-diaminopyrimidine, an Active-Site-Directed Irreversible Inhibitor of Dihydrofolic Reductase

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Irreversible enzyme inhibitors. 197. Water-soluble reversible inhibitors of dihydrofolate reductase with potent antitumor activity derived from 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-phenyl-s-triazine

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Irreversible enzyme inhibitors. CXXIX. p-(4,6-diamino-1,2-dihydro-2,2-dimethyl-s-triazin-1-yl)phenylpropionylsulfanilyl fluoride, an active-site-directed irreversible inhibitor of dihydrofolic reductase. V. Effects of substitution on the benzenesulf

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Irreversible enzyme inhibitors. 173. Cure of Walker 256 ascites by reversible and irreversible inhibitors of dihydrofolic reductase derived from 1-(substituted-phenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-s-triazine

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Active-site directed irreversible inhibitors of dihydrofolate reductase

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Stereochemistry of dihydrofolate reductase inhibitor antitumor agents: molecular structure of "Baker's antifol" (NSC 139105, triazinate) and "insoluble Baker's antifol" (NSC 113423)

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Correlation analysis. Its application to the structure-activity relation of triazines inhibiting dihydrofolate reductase

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

A general QSAR for dihydrofolate reductase inhibition by 2,4-diaminotriazines based upon molecular shape analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline (tmq), a potent non-classical folate antagonist inhibitor--I effect on dihydrofolate reductase and growth of rodent tumors in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Quinazolines as inhibitors of dihydrofolate reductase. 3. Analogs of pteroic and isopteroic acids.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Inhibition of dihydrofolate reductase: structure-activity correlations of quinazolines based upon molecular shape analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Distance geometry approach to rationalizing binding data

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Condensed pyrimidine systems. XXIII. Synthesis of 2,4-diaminopyrido[2,3-d]pyrimidines from .beta.-oxo esters

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Studies on condensed pyrimidine systems. XXIV. The condensation of 2,4,6-triaminopyrimidine with malondialdehyde derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Antimalarial substances. 26. Folate antagonists. 4. Antimalarial and antimetabolite effects of 2,4-diamino-6-[(benzyl)amino]pyrido[2,3-d]pyrimidines

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Synthesis and antitumor activity of 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

Elevation of brain histamine levels by diaminopyrimidine inhibitors of histamine N-methyl transferase

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970332-1

7 January 2021

10.1016/S0079-6468(08)70332-1

Identifiers

DOI

0 references

PubMed ID

6129679

1 reference

PubMed ID

6129679